An observational study in Parkinson's Disease, sponsored by AbbVie. Recruiting at 26 sites in 9 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by AbbVie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Parkinson Disease by AbbVie — 5 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · AbbVie.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 13th largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2026, is one of 18 observational ones, and was the 42nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in Spain
Ages 18+
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Germany
Ages 18–67
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 63 across the 25 interventional studies, 131 across the 18 observational. Of the 34 that completed or were terminated, 18 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
5 of the studies in Parkinson Disease by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07284342AbbVieA Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa | 2027-01 |
| NCT05916157AbbVieAn Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease | 2027-01 |
| NCT06639620AbbVieStudy To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting | 2027-03 |
| NCT06965374AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease | 2027-06 |
| NCT07227896AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Parkinson Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice.
Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world.
Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months.
There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being
The criteria were revised on the registry on Nov 10, 2026. See what changed
Participants with earlier within advanced Parkinson disease receiving Foslevodopa/Foscarbidopa treatment in accordance with the local label requirements in the participating country.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label.
Change From Baseline in motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)
Time frame: Up to approximately 6 months
Change From Baseline to "Off" Time Duration (absolute hours) and Severity, as measured by the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Item 4.3 and 4.4 scores
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)
Time frame: Up to approximately 6 months
Change From Baseline in Dyskinesia presence, impairment and disability, as measured by Unified Dyskinesia Rating Scale (UDysRS) total score
The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.
Time frame: Up to approximately 6 months
Change From Baseline in Dyskinesia duration (absolute hours) and severity, as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV, Item 4.1 and 4.2 score
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)
Time frame: Up to approximately 6 months
Change From Baseline in Disease-specific Quality of Life (QoL) as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).
Time frame: Up to approximately 6 months
Change From Baseline in Generic Quality of Life (QoL) as measured by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L)
The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each item is scored from 1 (best) to 5 (worst). An increase in the EQ-5D-5L score indicates a worsening.
Time frame: Up to approximately 6 months
Change From Baseline in Motor experiences of daily living as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.
Time frame: Up to approximately 6 months
Change From Baseline in Disease-specific sleep disturbances as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score
The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\] with the exception of Question 1 score ranging from 0 \[very often\] to 4 \[never\]).
Time frame: Up to approximately 6 months
Change From Baseline in Symptom severity measured by the Patient Global Impression of Severity (PGI-S) questionnaire.
The Patient Global Impression of Severity (PGI-S) is a single, patient-reported item that assesses the subject's perceived level of symptoms over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "no symptoms" (1) to "very severe" (5), with higher scores indicating greater severity.
Time frame: Up to approximately 6 months
Change From Baseline in Clinician-Reported Symptom Severity measured by the Clinical Global Impression of Severity (CGI-S) questionnaire.
Clinical Global Impression of Severity (CGI-S) is a 5-point rating scale that requires the clinician to assess the severity of the participant's illness. Scores range from 1=normal; to 5=very severe.
Time frame: Up to approximately 6 months
Change From Baseline in Patient-Reported Symptom Change measured by the Patient Global Impression of Change (PGI-C) questionnaire
The PGI-C is a participant's rating of the change in their PD-related symptoms since initiation of study drug. Participants rate their change in status using the following 7-point scale: 1 = Very much improved; 7 = Very much worse.
Time frame: Up to approximately 6 months
Change From Baseline in Clinician-Reported Symptom Change measured by the Clinical Global Impression of Change (CGI-C) questionnaire.
The Clinical Global Impression of Change (CGI-C) is a clinician's impression of a subject's change in status on a 7-point scale. CGI-C scores range from 1 = very much improved to 7 = very much worse.
Time frame: Up to approximately 6 months
Change From Baseline in morning akinesia (early morning "off") as measured by by dedicated questionnaire.
Measured by dedicated questionnaire.
Time frame: Up to approximately 6 months
Change From Baseline in the Presence and Frequency of Early Morning Dystonia, as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) single item 12
The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\] with the exception of Question 1 score ranging from 0 \[very often\] to 4 \[never\]).
Time frame: Up to approximately 6 months
Change From Baseline in Activities of daily living/independence as measured by the Schwab-England Activities of Daily Living (SE-ADL) Scale
The Schwab and England ADL (Activities of Daily Living) scale assesses the capabilities of people with impaired mobility. The scale uses percentages to reflect the effort and dependence on others people that are needed to complete daily chores." The results reported are between 0% (bedridden) and 100% (healthy).
Time frame: Up to approximately 6 months
Change From Baseline in Self-efficacy as measured by the Self-efficacy for Managing Chronic Disease Scale (SEMCD)
Self-efficacy for Managing Chronic Disease Scale (SEMCD) Self-efficacy for chronic disease will be measured. 6 items 1 to 10 each. 1 = not confident 10 = total confident.
Time frame: Up to approximately 6 months
Change From Baseline in Ability to Reintegrate Into Normal Social Activity After Illness as measured by the Reintegration to Normal Living Scale (RNLI) Scale
The Reintegration to Normal Living Index (RNLI) assesses how well individuals resume everyday activities and participate in their communities following illness or injury. It covers areas such as mobility, daily functioning, and self-perception, and includes 11 items scored on a 0-10 scale, with higher scores indicating greater reintegration into normal living.
Time frame: Up to approximately 6 months
Change From Baseline in Treatment satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score (TSQM-9)
Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score. an instrument used to measure how satisfied adult patients are with their medications. The scale consists of 9 items with 5 or 7 Likert scale answering options.
Time frame: Up to approximately 6 months
Change From Baseline in Stigma as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).
Time frame: Up to approximately 6 months
Healthcare Resource Utilization (HRU)
Healthcare Resource Utilization (HRU) is measured from initiation of the therapy and captures eg physician visits, hospital stays and engagement with other supporting therapists.
Time frame: Up to approximately 6 months
Number of Participants achieving monotherapy with Foslevodopa/Foscarbidopa (LDp/CDp)
Percentage of patients achieving monotherapy with LDp/CDp at month 3 and month 6
Time frame: Up to approximately 6 months
Questionnaire to investigate the practicalities of the infusion system
Questionnaire to investigate the practicalities of the infusion system (e.g., vial consumption, frequency of infusion-site rotation, nighttime dose adjustments).
Time frame: Up to approximately 6 months
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.
Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 14 months is below that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.